KA/EN
Register
Medicines reference
Search
Search
Product

Purevax RCPCh

Favourites

Feline herpesvirus + Feline calicivirus + Chlamydophila felis + Feline parvovirus · Boehringer Ingelheim Animal Health France SCS

1 form: suspension. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Form Species Dose Frequency Georgia
Suspension · Cat Cat 0.5 ml
Reconstitute with the 0.5 ml solvent presentation and inject one dose subcutaneously. Give the first dose from 8 weeks and the second 3-4 weeks later; delay until 12 weeks when high maternal antibody is expected. Revaccinate all components after one year; thereafter vaccinate the Chlamydophila component annually and the rhinotracheitis, calicivirus and panleucopenia components at intervals up to 3 years. Vaccinate healthy cats only. Do not use throughout pregnancy or lactation. Immunodeficient people or people taking immunosuppressants should not handle this live chlamydial vaccine.
 · two-dose primary series, then component-specific revaccination		 two-dose primary series, then component-specific revaccination Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: პურევაქსი RCPCh
№ 208-11; 39-11
Verified on: 20 Oct 2026
Details: pack, label wording, sources, registration

Purevax RCPCh, Suspension

lyophilisate and solvent for injection, 0.5 ml dose for cats
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Cat
8.2/10
Very good
vetman assessment

Purevax RCPCh

lyophilisate and solvent for injection, 0.5 ml dose for cats
Assessed clinical scopeCat · Full cat label: active immunisation against FHV, FCV, panleucopenia and Chlamydophila felis with the labelled primary course and component-specific revaccination · Subcutaneous
Care settingRisk-based preventive vaccination in a clinic able to assess multi-cat exposure, maintain cold chain and manage accidental exposure or hypersensitivity
vetman score 8.2/10 Very good
Evidence confidence: High Georgia: Yes, veterinary · № 208-11; 39-11 · Verified on 20 Oct 2026

A strong core vaccine with a legitimate but situational Chlamydophila add-on. It is an attractive choice in documented high-risk multi-cat environments, but routine use in every cat adds annual vaccination and live-organism handling without equivalent universal benefit.

Regulatory and scientific credibility9.0/10

The exact 0.5 ml product is registered in Georgia and supported by a current SPC plus a regulator assessment that transparently separates each antigen claim, challenge result, schedule and safety limitation.

Clinical efficacy7.9/10

The RCP core components are well supported and durable. The Chlamydophila component is non-core, appropriate mainly for high-risk multi-cat settings, and reduces clinical signs without reliably preventing infection or shedding; its inclusion should therefore follow a specific risk assessment.

Safety and tolerability8.0/10

Expected reactions are usually transient and the product is non-adjuvanted, but it contains live chlamydial organisms; pregnancy and lactation use is contraindicated, and immunodeficient or immunosuppressed people should not handle it.

Clinical practicality7.8/10

The fixed 0.5 ml dose is straightforward, but the annual Chlamydophila component, separate longer core intervals, risk selection, reconstitution, cold chain and handler restrictions make the programme more complex than RCP alone.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Vaccinate healthy cats only; do not use in hypersensitivity to a component.
  • Do not use during pregnancy or lactation.
  • Use the Chlamydophila component only for documented higher-risk multi-cat settings; it is not a routine core antigen for every cat.
  • Chlamydophila vaccination reduces clinical signs but does not reliably prevent infection or bacterial shedding.
  • Immunodeficient people or people receiving immunosuppressants should not handle this live chlamydial vaccine; seek medical advice after accidental exposure.
  • Monitor hypersensitivity and transient local or systemic reactions; have immediate treatment available.
  • Revaccinate Chlamydophila annually while risk persists, separate from the longer core-component interval; maintain cold chain and use promptly after reconstitution.
Assessment sources
  1. VMD SPC 20262026
  2. Purevax RCCh EPAR2004
  3. WSAVA vaccination 20242024
  4. AAHA/AAFP feline vaccination 20202020
  5. ABCD C felis guideline 20262026
  6. Purevax three-year challenge2015
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Feline herpesvirus4.9 log10 CCID50/dose Feline calicivirus2 ELISA U/dose Chlamydophila felis3 log10 EID50/dose Feline parvovirus3.5 log10 CCID50/dose
Formulation Type
Suspension
Administration route
Subcutaneous
Manufacturer (register)
SCS Boehringer Ingelheim Animal Health France SCS, France
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 1314, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: პურევაქსი RCPCh
№ 208-11; 39-11
Verified on: 20 Oct 2026
Controlled in Georgia
Unknown
DoseSpeciesWeightRouteFrequencySource
0.5 ml
Reconstitute with the 0.5 ml solvent presentation and inject one dose subcutaneously. Give the first dose from 8 weeks and the second 3-4 weeks later; delay until 12 weeks when high maternal antibody is expected. Revaccinate all components after one year; thereafter vaccinate the Chlamydophila component annually and the rhinotracheitis, calicivirus and panleucopenia components at intervals up to 3 years. Vaccinate healthy cats only. Do not use throughout pregnancy or lactation. Immunodeficient people or people taking immunosuppressants should not handle this live chlamydial vaccine.
 Cat Any weight Subcutaneous two-dose primary series, then component-specific revaccination
VMD SPC 2026
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Purevax RCPCh - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2026

Feline herpesvirus: No dose supported by a publicly verifiable source yet

Feline calicivirus: No dose supported by a publicly verifiable source yet

Chlamydophila felis: No dose supported by a publicly verifiable source yet

Feline parvovirus: No dose supported by a publicly verifiable source yet

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 21 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗